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Abstract 
The primary role of epinephrine for the treatment of ventricular fibrillation (VF) and pulseless electrical activity 
(PEA) is to increase blood flow to the myocardium and central nervous system and ultimately improve survival. HOW- 
ever, despite the administration of epinephrine, survival following VF or PEA is low. In an attempt to improve out- 
come from VF and PEA, alternative adrenergic agonists (methoxamine, phenylephrine, norepinephrine) which have 
different pharmacological properties than epinephrine have been evaluated. In order to determine the role of alterna- 
tive adrenergic agonists for the treatment of VF and PEA this paper will compare the pharmacological properties and 
pharmacodynamic effects of these drugs to epinephrine. Specifically, receptor physiology along with the effects of adre- 
nergic agonists on coronary perfusion pressure, survival, myocardial oxygen demand, and cerebral blood flow will be 
discussed. 
Keywords: Resuscitation; Epinephrine; Methoxamine; Phenylephrine; Norepinephrine; Ventricular fibrillation; 
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1. Introduction 
According to standard Advanced Cardiac Life 
Support (ACLS) guidelines epinephrine is con- 
sidered a first line drug in the treatment of ventric- 
ular fibrillation and pulseless electrical activity 
(PEA) [l]. Because of its adrenergic properties, 
epinephrine is widely used during cardiac arrests. 
However, the outcome of patients experiencing 
ventricular fibrillation or PEA remains poor 
despite treatment with epinephrine [2,3]. One at- 
tempt to improve outcome from a cardiac arrest is 
to determine if other drugs with adrenergic proper- 
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ties (methoxamine, phenylephrine, norepine- 
phrine) may be more effective than epinephrine. 
Theoretically, pharmacological differences among 
vasoactive drugs may result in differences in out- 
come from cardiac arrest. This paper will evaluate 
the differences among adrenergic drugs in regards 
to pharmacological properties and efficacy in the 
treatment of ventricular fibrillation and PEA. 
2. Adrenergic physiology and properties 
The adrenergic system consists of two distinct 
receptor types, (Y- and P-adrenoreceptors. These 
receptors can be further subclassified as q-, (Ye-, 
PI-, and &-adrenoreceptors (Table 1). Adrenergic 
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Table 1 











receptors are located throughout the body with the 
peripheral and cardiac adrenergic receptors being 
the most important during ventricular fibrillation 
and PEA due to the ability to increase systemic 
and cornary perfusion pressures [41. aI- 
Adrenoreceptors are located postsynaptically 
while cr,-receptors appear to be located both 
presynaptically and postsynaptically [4-61. The 
effect of postsynaptic ol- and a2-receptor stimula- 
tion in smooth muscle is excitatory and mediates 
vasoconstriction [4-61. Stimulation of presynaptic 
a2-receptors inhibits the neural release of 
norepinephrine through feedback inhibition [6]. 
The effects of /3, stimulation include increases in 
myocardial contractility and heart rate whereas 
the stimulation of f12-receptors results in vasodila- 
tion of vascular smooth muscle [6]. 
The degree of stimulation of Q- and &receptors 
by adrenergic agonists during a cardiac arrest is 
important since coronary perfusion pressure and 
aortic diastolic pressures are major determinants 
of successful resuscitation [7-91. Perfusion of the 
coronary arteries occurs during the relaxation 
phase of external chest compressions during 
cardiopulmonary resuscitation (CPR) and is 
represented by coronary perfusion pressure [lo]. 
Coronary perfusion pressure is defined as the dif- 
ference between aortic diastolic and right atria1 
diastolic pressures [8,11]. Since right atria1 
diastolic pressure does not vary greatly during 
CPR, aortic diastolic pressures may also represent 
myocardial blood flow as well as being an indica- 
tor of the ability to resuscitate. Adrenergic agon- 
ists are administered during CPR to increase aortic 
diastolic pressure, coronary perfusion pressure 
and thus resuscitation. Adrenergic agonists im- 
prove aortic and coronary perfusion pressures 
along with myocardial and cerebral blood flow 
due to stimulation of a-receptors. This results in 
vasoconstriction of smooth muscles, increases in 
perfusion pressures, and prevention of arterial col- 
lapse, which otherwise may occur secondary to 
high intrathoracic pressures generated during 
CPR [6,12-141. 
In addition to epinephrine, other adrenergic 
agonists have been used during ventricular fibrilla- 
tion and PEA, including norepinephrine, 
phenylephrine, and methoxamine. There are a 
number of differences among these adrenergic 
agonists including CY- and b-receptor activity 
(Table 2). Epinephrine is considered to be a mixed 
(Y and P-agonist with ol, (112, /3t, and P2 properties 
[6,15]. Norepinephrine agonist properties are 
similar to those of epinephrine except that the P2 
adrenergic activity of norepinephrine is negligible 
compared to epinephrine [6]. Phenylephrine and 
methoxamine are considered selective al-agonists 
with minimal 02, &, or f12 adrenergic properties 
[W51. 
Differences in receptor stimulation between the 
adrenergic agonists may have theoretical advan- 
tages and disadvantages during CPR. It is known 
that CY adrenergic properties are required for 
peripheral vasoconstriction which leads to increas- 
ed coronary perfusion pressure and potential im- 
proved survival. However, there may be 
differences in the ability of al- and a2-receptors to 
cause vasoconstriction. There is evidence to sug- 
gest that stimulation of orreceptors by drug ther- 
apy may be more important in causing 
vasoconstriction than crl-receptor stimulation 
[ 16,171. One potential explanation for differences 
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located extrajunctionally along the intima of the 
vessel walls and may be more accessible than 
or,-receptors to the effects of circulating 
catecholamines especially in ischemic states due to 
their location [4,16,18,19]. Because of the location 
of orz-receptors, drugs which stimulate cy2- 
receptors may result in more vasoconstriction than 
drugs that stimulate only al-receptors. Differ- 
ences in o,- and a2-receptor density during 
ischemia is another explanation for the potential 
increased importance of a2-receptors during CPR. 
It has been hypothesized that during &hernia 
there may be a down-regulation of al-receptors 
with an increase in ar2-receptors (or binding sites) 
[20-221. However, it should be emphasized that 
this hypothesis is based in part on a study that 
demonstrated an increase in ar2-binding sites in rat 
vas deferens [21]. It is unknown if this same effect 
occurs in humans during CPR. 
Beta adrenergic receptor stimulation without 
concurrent (II adrenergic stimulation during CPR 
has been shown not to improve survival, probably 
due to vasodilation of the peripheral circulation 
[ 121. However, the combination of a and fl proper- 
ties may be beneficial. Alpha receptor stimulation 
will result in peripheral vasoconstriction (as 
previously discussed), while P adrenergic stimula- 
tion may improve cerebral blood flow by 
vasodilating the cerebral vasculature and may also 
decrease the energy needed for defibrillation 
[23-261. Despite the potential benefit with com- 
bination of a! and fi properties there is still a con- 
cern about 0 adrenergic effects during CPR. This 
concern includes not only the peripheral vasodila- 
tion that may occur with f12 stimulation but also 
the potential effect of increasing myocardial 
oxygen demand and decreasing high energy 
phosphates secondary to PI stimulation. 
Briefly, high energy phosphates which includes 
but not limited to adenosine triphosphate (ATP), 
adenosine diphosphate, and phosphocreatine are 
important in that they provide the necessary 
energy for myocardial function. During ventricu- 
lar fibrillation high energy phosphates are decreas- 
ed [27,28]. It is hypothesized that if high energy 
phosphates are decreased beyond a critical point, 
resuscitation is not possible. Theoretically, a po- 
tential concern with adrenergic agonists with /3, 
properties is that myocardial energy requirements 
and oxygen demands may be increased to a greater 
extent than which myocardial oxygen can be 
delivered. This may result in further decrease in 
high energy phosphates and a limited ability to 
resuscitate a patient. Whether or not this occurs 
is not certain. One study compared myocardial 
ATP concentrations between 10 dogs receiving 
epinephrine (1 mg bolus followed by 0.2 mg/min) 
to 10 controlled dogs undergoing CPR [29]. The 
results demonstrated that myocardial ATP con- 
centrations decreased significantly from baseline 
but the decrease was comparable between the two 
groups. In a different study, standard dose 
epinephrine (0.02 mg/kg) was compared to high 
dose epinephrine (0.2 mg/kg) in swine undergoing 
CPR on myocardial high energy phosphates [30]. 
This study demonstrated a significant increase in 
coronary perfusion pressure and phosphocreatine 
for the high dose epinephrine group as compared 
to standard dose epinephrine group. This study 
suggests that high dose epinephrine may help im- 
prove myocardial energy stores in part due to in- 
creasing myocardial blood flow (i.e. coronary 
perfusion pressure) and potentially the myocardial 
oxygen delivery to demand ratio. Another study in 
dogs undergoing CPR, suggests that by blocking 
P-receptors with propranolol and administering 
phenylephrine that ATP concentrations can be 
significantly improved compared to control (311. 
These results may be due to the fact that the com- 
bination of phenylephrine and propranolol ap- 
peared to have the greatest effect on coronary 
perfusion pressure. However, it should be noted 
that there was no difference between this group 
and the epinephrine treatment group in regards to 
ATP concentrations, although the phenylephrine 
and propranolol group did have higher ATP con- 
centrations (29.5 f 3 vs. 19.2 & 1.6 nmol/mg of 
protein). Overall then, the (3, effects of adrenergic 
agonists on myocardial oxygen demand and high 
energy phosphates may be negligible if oxygen de- 
livery can be increased to exceed oxygen demand. 
With additional studies, /3-blockers may also be 
proven to be beneficial during CPR in regards to 
improving high energy phosphate levels. However, 
more studies are needed to clearly delineate the fll 
effects of adrenergic agonists during CPR. A more 
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complete review of high energy phosphates may be 
found elsewhere [32]. 
In discussing receptor physiology and the effect 
of adrenergic agonist the role of adenosine needs 
to be mentioned. Adenosine receptors are located 
in the myocardium and vascular system. Adeno- 
sine receptors may be classified as Al and A2 
receptors [33-351. Al receptors are located on the 
myocardium and A2 receptors on vascular smooth 
muscle. Stimulation of Al receptors results in neg- 
ative chronotropic and dromotropic actions. A2 
receptor stimulation results in vasodilation of the 
coronary arteries. The exact mechanism by which 
adenosine causes vasodilation is unknown, but ap- 
pears to invoke, in part, endothelium. 
The role of adenosine during CPR has not been 
completely elucidated, however, data from other 
ischemic and reperfusion models suggest an im- 
portant role. This role may include coronary 
vasodilation (with improvement of coronary blood 
flow), decrease inotropic effect secondary to & 
stimulation (may decrease oxygen demand and 
preserve high energy phosphates), preserve myo- 
cardial function post ischemic event, inhibit neu- 
trophil activation and free radical generation 
[36-401. The importance of the vasodilating action 
of adenosine during CPR was suggested in a recent 
study [41]. In this study, adenosine (100 &kg per 
min) was administered to rats undergoing CPR. 
The results demonstrated similar survival between 
the adenosine and control groups (6/7 vs. 4/7 for 
adenosine and control animals, respectively). 
However, what was most interesting was that the 
coronary perfusion pressure was significantly 
lower in the adenosine group as compared to the 
control group (7 f 2 vs. 22 f 3 mmHg; P < 0.01, 
respectively) and yet survival was similar. Based 
on these findings, the authors suggest that adeno- 
sine induced vasodilation may increase coronary 
reserve which may result in increase coronary 
blood flow despite low coronary perfusion 
pressure. 
Another important aspect in regards to adeno- 
sine and CPR therapy is that adrenergic agonists 
may play a role in the regulation of endogenous 
adenosine. It has been shown that crt adrenergic 
stimulation during ischemia may enhance adeno- 
sine release and that a2 adrenergic stimulation 
modifies the vasodilatory action of adenosine 
[42-451. These findings have lead to the hypothe- 
sis that q and o2 adrenergic stimulation during 
&hernia may play an important role in the effects 
of adenosine. If this hypothesis is true, then adre- 
nergic therapy during CPR may have a greater role 
then just causing vasoconstriction. This hypothesis 
also suggests that a pure q- or cr2-agonist may 
not be as beneficial during CPR as mixed (Y,- and 
a2-agonists. 
3. Ventricular fibrillation 
3. I. Coronary perfusion pressure and survival 
The results of studies evaluating adrenergic 
agonists in animal models are shown in Table 3. In 
comparing the effects of intravenous phenyle- 
phrine to epinephrine, earlier studies suggested 
that these agents had similar effects on survival 
[46-481. In another study in dogs intravenous 
phenylephrine (0.4 mg/kg bolus at the onset of 
CPR and 5 min after) was compared to intrave- 
nous epinephrine (0.2 mg/kg bolus at the onset of 
CPR and 5 min after) and to phenylephrine plus 
propranolol (1 mg/kg at the onset of CPR) [31]. 
For the experimental protocol ventricular fibrilla- 
tion was induced followed immediately by CPR, 
each treatment group described above and a con- 
trol group evaluated six dogs each. From the re- 
sults reported it appears that after the first bolus 
dose of drug there was a similar increase in coro- 
nary perfusion pressure. However, after the 5-min 
time point the phenylephrine plus propranolol 
group appeared to have a higher pressure response 
and was able to sustain this response over time. 
Unfortunately, actual values were not reported 
and it appears that the differences was not 
statistically significant despite the apparent visual 
differences. The authors suggested that the reason 
for the better response to the phenylephrine and 
propranolol group was due to propranolol’s abili- 
ty to block &receptors and allowing for unoppos- 
ed (Y adrenergic stimulation. They also suggested 
that /3 blockade may increase coronary flow by 
decreasing the force of ventricular fibrillation. 
However, a different study in pigs with rigorous 
evaluation of coronary perfusion pressure and 
B.E. Bleske. J.E. Billi / Resuscitation 28 (1994) 239-251 243 
Table 3 
Animal CPR models 
Ref. VF CPR Drug Do& Model N CPPn 
(min) (mm) 























































































5 2.3 ??3.3 
5 24.8 f 6.8 
5 13 + 5.3 
5 16 * 6.9 
5 9.2 f 12.4 
5 12.4 f 8.9 
5 23.5 f 13.6 
5 9.2 f 12.4 
5 4.2 f 6.5 
5 9.2 zk 5.2 


















7 6.1 EIE 11.4 
7 6.8 t 9.1 
7 
7 
40.3 f 4.1 5.4 f 2.5 
24.4 + 6.2 3.3 f 2.6 
13 * 11.5 4.7 f 5.9 
14 ??6.2 8.8 zt 8.9 
42.6 f 5.3 5.2 i 3.4 
10.3 ?? 10 6.6 zt 7.6 
14.8 f 19.6 13.3 f 20 
42.6 zt 5.3** 5.2 ??3.4 
18.8 f 9.8 3.1 * 2.1 
48.4 ??8.6** 11.7 f 12 






19.2 + 7.8 
20.0 f 6.0 
32 jz 8 
30 h 6 
40.0 i 6.3 5.1 + 3.0 
25.9 zrz 13.5 3.0 + 2.5 
71 * 10 
74* 11 
117.7 + 58.3. 4/S 
14.8 + 30.4 l/5 
9.1 * 9.9 o/5 
20.6 zt 11.2 o/5 
67.2 i 49.4” 4/5 
7.0 * 7.1 o/5 
36.7 + 21.1 o/5 
69.1 f 53.1 415 
35.5 * 39 205 
94.5 f 15.4 515 











25 f 15 l/6 
24.3 +z 10.7 116 





62.2 f 45.3 617 
118.9 r+ 73.1: 4/7 
126 zt 18 3I7 
107*30 7r7 
VF, ventricular fibrillation; CPR, cardiopulmonary resuscitation; CPPn, coronary perfusion pressure baseline (mmHg); CPP,, coro- 
nary perfusion pressure post-drug administration; MBFn, myocardial blood flow baseline (ml/min per 100 g); MBFr, myocardial 
blood flow post-drug administration; E, epinephrine; P, phenylephrine; M, methoxamine; N, norepinephrine. 
BValues in bold type are mgkg; values in normal type are mg; values in italic type are &kg. 
*P < 0.05, compared to methoxamine. 
**P < 0.05, compared to 0.08 mgkg NE. 
tP < 0.01, compared to epinephrine. 
$P = 0.04, compared to epinephrine. 
OEpinephrine 0.2 mgkg and phenylephrine 1.0 mgkg were significantly better (P = 0.009) than phenylephrine 0.1 mgkg. 
myocardial blood flow suggests that epinephrine is phenylephrine and epinephrine, respectively). In 
more effective than phenylephrine [ 171. In this another study by the same author with similar 
study, equivalent pressor doses of phenylephrine design as the previous study, intravenous 
was stated to be approximately five times that of epinephrine (0.2 mg/kg) was compared to intrave- 
epinephrine (1 mg/kg vs. 0.2 mg/kg for nous phenylephrine (1 .O mg/kg and 10 m&kg) in 
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swine (n = 5 for each group) [49]. Although, no 
coronary perfusion pressure values were reported, 
aortic diastolic pressure values were. For the 
epinephrine group, aortic diastolic pressures in- 
creased from 9 f 8 to 31 f 23 mmHg (pre- to 
post-drug), for the 1 .O mg/kg phenylephrine group 
pressure changed from 26 * 13 to 25 f 12 
mmHg, and for the 10 mg/kg phenylephrine group 
pressure increased from 19 f 12 to 36 f 22 
mmHg. There was no significant differences be- 
tween the groups despite the greater increase in the 
epinephrine group. Similar results were seen in an 
earlier study by the same author [50]. In this study 
in which the study design was similar to the pre- 
vious study, intravenous epinephrine 0.2 mg/kg 
was compared to intravenous phenylephrine 0.1 
mg/kg. The results demonstrated that there was an 
increase in aortic diastolic pressure (no coronary 
perfusion pressure values were reported) following 
epinephrine therapy (18.5 f 4.9 to 31 f 19.1 
mmHg) whereas there was a decrease following 
phenylephrine therapy (19.4 f 8.3 to 14.6 f 7.7 
mmHg). Overall it appears that phenylephrine 
may increase pressures in high enough doses but it 
is questionable whether or not it has similar 
magnitude of response as epinephrine. Differences 
in animal species and study design may account 
for the differences seen between studies. Specitical- 
ly, for study design, differences in dose of drug 
used, the time in ventricular fibrillation, the time 
when CPR was started and stopped, time drug was 
administered, and pressure measurements (earlier 
studies pressure changes were not reported or con- 
trolled for at baseline) may all effect the results of 
a study. For example, the longer an animal is in 
ventricular fibrillation and undergoing CPR the 
less likely they are to response to drug therapy or 
to survive. In regards to the use of different species 
of animals, differences in the physiology of the 
heart (swine appear to have coronary circulation, 
collateral circulation, and conduction system more 
similar to humans than canines do) along with 
receptor distribution between species may alter the 
response to drug therapy [Sl-541. These differ- 
ences make if difIicult to compare studies across 
different species. 
A study by Brown et al. in pigs showed that high 
dose epinephrine (0.2 mg/kg) resulted in a greater 
increase in coronary perfusion pressure and myo- 
cardial blood flow (P < 0.05) as compared to 
three different doses of intravenous methoxamine 
[ 161. There was also a trend demonstrating im- 
proved survival in the epinephrine group. In con- 
trast, a study in dogs showed that methoxamine 
significantly improved survival (P c 0.01) com- 
pared to epinephrine following a prolonged CPR 
period, despite similar increases in blood flow to 
the left ventricle [55]. The differences in survival 
may be accounted for by the finding that aortic 
diastolic pressures were significantly higher at 15 
and 20 min after the start of ventricular fibrillation 
for the methoxamine group. Other animal studies 
demonstrated similar survival between methox- 
amine and epinephrine [46,47,56]. Unfortunately, 
there is limited information regarding coronary 
perfusion pressure and myocardial blood flow 
given in these studies. Overall, positive results for 
both methoxamine and epinephrine were seen, dif- 
ferences in protocol design and resuscitation 
techniques make comparisons among studies dif- 
ficult. It is interesting to note that positive results 
for methoxamine occurred in the dog models and 
not in the pig models, suggesting interspecies dif- 
ferences. Interspecies differences includes as men- 
tion above myocardial physiology and receptor 
density. In regards to receptor differences, one 
study showed that in isolated arteries, greyhound 
arteries had a greater response than pig arteries to 
norepinephrine [54]. This suggest differences in 
receptor density and may account for differences 
seen between swine and canine models. 
Four recent studies have compared epinephrine 
to norepinephrine in pigs [20,57-591. One dose 
ranging study demonstrated similar effects be- 
tween high dose epinephrine (0.2 mg/kg) and 
norepinephrine doses of 0.12 mg/kg and 0.16 
mg/kg on coronary perfusion pressure and myo- 
cardial blood flow [20]. Similar effects were also 
seen with the same dose (0.045 mg/kg) of 
epinephrine and norepinephrine in two other stud- 
ies [57,59]. In a fourth study, 0.2 mg/kg of 
norepinephrine significantly improved (P = 0.04) 
myocardial blood flow compared to 0.2 mg/kg of 
epinephrine; however, epinephrine tended to 
increase coronary perfusion pressure to a greater 
extent [58]. There appeared to be no difference in 
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survival between the two agents among the studies. 
Overall, it appears that norepinephrine and 
epinephrine have similar effects on coronary per- 
fusion pressure, myocardial blood flow, and 
survival. 
3.2. Myocardial oxygen demand 
One issue that has been raised with the use of 
epinephrine is its 0, adrenergic effect on the heart 
during cardiac arrest. Stimulation of &-receptors 
produces inotropic and chronotropic effects in the 
normal heart. During ventricular fibrillation, the 
ability to increase heart rate is probably irrelevant, 
however, the effect on the force of contraction and 
cellular metabolism (including decreasing high 
energy phosphates as previously described) may 
not be [4]. A number of studies have attempted to 
evaluate the effects of adrenergic agonists with PI 
adrenergic properties (epinephrine) on myocardial 
energetics and oxygen demand compared to adre- 
nergic agonists with minimal or no & properties 
(phenylephrine, methoxamine, norepinephrine) 
[16,17,20,56-611. Brown et al. (Table 3) compared 
the effects of epinephrine and phenylephrine on 
myocardial oxygen delivery, consumption, and 
myocardial oxygen extraction ratio in pigs [ 171. 
There was a statistically significant increase in 
myocardial oxygen delivery during CPR post 
drug delivery for epinephrine 0.2 mg/kg and 
phenylephrine 1 mg/kg compared to phenyl- 
ephrine 0.1 mg/kg (10.6 f 7.5 vs. 5.3 f 3.6 vs. 
1.0 f 1.2 ml Oz/min per 100 g, respectively). 
Similarly, myocardial oxygen consumption 
statistically increased for epinephrine and the 
higher phenylephrine dose compared to the lower 
phenylephrine dose (7.6 f 4.4 vs. 4.8 f 3.1 vs. 
1.0 f 1.1 ml Oz/min per 100 g, respectively). 
However, the oxygen extraction ratio was 
significantly lower with epinephrine compared to 
both doses of phenylephrine (76.6 f 10.5% vs. 
90.7 f 7.5% vs. 94.6 f 4.0%, respectively), which 
suggests that higher oxygen delivery with 
epinephrine more than offset higher oxygen con- 
sumption. The results from this study suggest that 
epinephrine improves both the delivery and use of 
oxygen more so than phenylephrine and that 8, 
adrenergic effects may not be deleterious to the 
balance of oxygen supply and demand. These ef- 
fects may not be the same in naturally occurring 
ischemic myocardium because of limits on the ab- 
ility to increase perfusion, which is usually second- 
ary to coronary stenosis. For example, the effect of 
coronary stenosis on coronary blood flow was 
evaluated in a study in swine, in which a 33% 
stenosis was induced prior to ventricular tibrilla- 
tion and closed chest CPR [62]. The results 
demonstrated that during CPR endocardial blood 
flow distal to the stenosis was significantly less as 
compared to blood flow proximal to the stenosis. 
As suggested by the study, coronary stenosis may 
limit the ability to increase blood flow following 
administration of an adrenergic agonist and thus 
allowing 19, effects to increase myocardial oxygen 
demand. 
In another study, epinephrine (5 &min) or 
phenylephrine (50 PgImin) was infused for 5 min 
during ventricular fibrillation in isolated dog 
hearts [60]. Coronary blood flow and myocardial 
oxygen consumption was significantly greater for 
epinephrine following 4 min of ventricular fibrilla- 
tion (30.9 f 11.7 ml/min per 100 g and 5.4 f 1.9 
ml O*/min per 100 g, respectively) than with 
phenylephrine (24.4 * 6.0 ml/min per 100 g and 
3.8 f 1.1 ml Oz/min per 100 g, respectively). In 
addition, 10 min after defibrillation, the slope of 
the end-systolic pressure volume relation was 
depressed with epinephrine, and increased with 
phenylephrine (72 f 17% vs. 143 * 17%, p c 
0.002, respectively). From these results, the 
authors concluded that left ventricular function 
declines following epinephrine administration, 
whereas function is preserved following 
phenylephrine use. Differences in the results of 
these studies by Brown et al. and Midei et al. may 
be accounted for by the different animal species 
used and the intact versus isolated models 
evaluated. Specifically, Brown used an intact ani- 
mal model in which closed chest CPR was per- 
formed which probably is more similar to a human 
CPR setting than an isolated heart model. Another 
difference between the two models is that coronary 
perfusion pressure was held constant and rather 
high (30 mmHg) in the isolated model which prob- 
ably does not reflect an actual CPR setting. 
Despite these limitations of an isolated model it 
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does provide for precise control of variables such 
as coronary perfusion pressure and allows for ac- 
curate measurements of other variables such as left 
ventricular function. It is not known which model 
is the best for determining the metabolic and 
physiological effects that occur following drug ad- 
ministration in humans. 
In comparing epinephrine to methoxamine, 
Brown et al. (Table 3) demonstrated in pigs that 
myocardial oxygen delivery was higher for 
epinephrine versus methoxamine in doses of 0.1 
mg/kg, 1.0 mg/kg, and 10 mg/kg (20.6 f 12.7 vs. 
5.2 f 6.8 vs. 2.8 f 2.9 vs. 3.4 f 0.9 ml 02/min 
per 100 g, respectively), as was myocardial oxygen 
consumption (15.6 f 10.1 vs. 4.4 f 5.8 vs. 
2.6 f 2.6 vs. 3.1 f 0.7 ml O*/min per 100 g, 
respectively) [16]. He also demonstrated that 
the oxygen extraction ratio for epinephrine was 
lower than with methoxamine (0.8 i 0.19 vs. 
0.93 f 0.09, 0.95 * 0.04 vs. 0.91 f 0.04). These 
data suggest that epinephrine improves myocardi- 
al oxygen delivery over utilization better than 
methoxamine. Another study (Table 3) demon- 
strated in dogs no difference between epinephrine 
and methoxamine in regards to systemic lactate, 
myocardial lactate, or myocardial oxygen extrac- 
tion ratios (-27 f 40 vs. -25 & 24, -101 f 116 
vs. -120 f 64, 90 f 9 vs. 86 f 61, respectively) 
[56]. These data suggest that the /3 adrenergic stim- 
ulating properties of epinephrine are not 
deleterious as compared to methoxamine in this 
model. 
In a third study, methoxamine 0.25 mg/kg per 
min or epinephrine 10 &kg per min continuous 
infusion was administered to five dogs on cardio- 
pulmonary bypass following ventricular fibrilla- 
tion [61]. The results showed that epinephrine may 
worsen myocardial ischemia by increasing oxygen 
demands (increasing intraventricular balloon pres- 
sure 24% and oxygen uptake 42%) while impeding 
subendocardial blood supply (endocardial/epicar- 
dial flow ratio decreased from 0.79 to 0.48). Con- 
versely, methoxamine did not significantly alter 
these parameters. One explanation for the differ- 
ence between the results of this and the other two 
studies is that cardiopulmonary bypass was used 
to maintain a high coronary perfusion pressure, 
which may not allow epinephrine or methoxamine 
to exert their physiological effects. 
There are three studies which evaluated 
norepinephrine and epinephrine. Unlike previous 
studies with phenylephrine and methoxamine, 
agents which lack both CQ and 6, and & adrener- 
gic activity, norepinephrine lacks significant & 
adrenergic properties compared to epinephrine. In 
the pig model, Robinson et al. (Table 3) showed a 
trend in which norepinephrine (0.12 mg/kg and 
0.16 mg/kg) improved myocardial oxygen delivery 
versus epinephrine (16.7 f 3.2 and 14.8 f 9.6 vs. 
10.5 f 7.4, respectively) as well as myocardial 
oxygen extraction (69.4 f 15.1 and 65.2 f 20 vs. 
76.7 f 11, respectively) [20]. A study evaluating 
45 &kg of epinephrine and norepinephrine in 
pigs showed that the myocardial oxygen extraction 
ratio for norepinephrine was significantly im- 
proved compared to epinephrine (37.3 f 9.8 vs. 
51.5 i 13; P < 0.05) [59]. However, another 
study evaluating 0.2 mg/kg of norepinephrine and 
epinephrine showed no difference in myocardial 
oxygen extraction ratio (77 f 13.4 vs. 78.2 f 13) 
between the two drugs while norepinephrine 
resulted in a significant increase in myocardial 
oxygen delivery (19.9 f 13.4 ml O#OO g vs. 
9.4 f 6.3 ml 02/100 g) and consumption 
(14.2 f 7.7 vs. 7 f 3.8 ml O,/lOO g) compared to 
epinephrine [58]. These data suggest that 
norepinephrine may have similar or more 
beneficial effects on myocardial oxygen delivery 
and demand than epinephrine. However, as 
previously discussed, high dose epinephrine may 
have beneticical effects on myocardial oxygen de- 
livery as seen by the effects on high energy 
phosphates [30]. 
In summary, results from the available studies 
suggest that the &-agonist effects of epinephrine 
as compared to phenylephrine and methoxamine 
may either improve or worsen oxygen metabolism 
during ventricular fibrillation and CPR. There are 
insufficient data to claim that /3, adrenergic effects 
are deleterious. However, as alluded to earlier, 
negative effects of /3, stimulation may become ap- 
parent when coronary stenosis is present due to 
diminished blood flow post coronary stenosis. In 
addition, it is important to realize that with only 
closed chest CPR there is an inadequate increase 
in coronary blood flow to meet the myocardial 
oxygen demands of the heart [10,63]. Therefore, 
any further increase in demand due to 6, stimula- 
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tion without adequate increase in perfusion may 
be detrimental. In regards to & adrenergic effects 
of epinephrine, there are data to suggest, although 
very limited, that agents which lack & effects, 
such as norepinephrine, may be more beneficial. 
3.3. Cerebral blood jlow 
In addition to myocardial hemodynamics, the 
effects of vasopressors on patient outcome may 
also relate to cerebral hemodynamics. The effects 
of epinephrine and phenylephrine on regional 
cerebral blood flow was evaluated in one study 
comparing intravenous epinephrine 0.2 mg/kg and 
phenylephrine 0.1 mg/kg in pigs [50]. The design of 
this study was similar to previous studies perform- 
ed by Brown et al. (Table 3) [ 171. Cerebral blood 
flow was measured by radionuclide microspheres. 
There was significantly greater improvement in 
cerebral blood flow (P < 0.02) following 
epinephrine administration as compared to 
phenylephrine in all areas of the brain measured 
(left and right cerebral cortex, cerebellum, mid- 
brain, pons, medulla, and cervical spinal cord). In 
a similar study, phenylephrine 1 mg/kg and 10 
mg/kg were compared to epinephrine 0.2 mg/kg in 
15 pigs [49]. Epinephrine was significantly better 
than the phenylephrine 1 mg/kg group in improv- 
ing regional cerebral blood flow, however, there 
was no difference in regional cerebral blood flow 
with epinephrine, compared to the 10 mg/kg 
phenylephrine group. 
In a similar study, the same author compared in- 
travenous epinephrine 0.02 mg/kg and 0.2 mg/kg 
to intravenous methoxamine 0.1 mg/kg, 1 mg/kg, 
and 10 mg/kg in pigs (n = 5 for each group) [25]. 
This study demonstrated that high dose 
epinephrine improved cerebral blood flow in all 
areas evaluated to a greater extent (P = 0.0001) 
than methoxamine. In a different study that has 
been previously described, methoxamine (20 mg) 
demonstrated similar increases in blood flow to 
different areas of the brain as epinephrine (0.2 
mg/kg every 3 min) 1551. 
In an another study by Brown et al. (similar pro- 
tocol design as his previous studies), epinephrine 
0.2 mg/kg was compared to norepinephrine 0.8 
mg/kg, 0.12 mg/kg, and 0.16 mg/kg in pigs (n = 5 
for each group) [64]. The results showed that in 
general there was no statistical differences in 
regional cerebral blood flow between epinephrine 
0.2 mg/kg and norepinephrine 0.16 mg/kg How- 
ever, both these doses improved cerebral blood 
flow to the lower brainstem structures greater than 
the 0.08 mg/kg dose of norepinephrine. 
Epinephrine 0.2 mg/kg has also been compared to 
norepinephrine 0.2 mg/kg in 14 pigs [58]. No signi- 
ficant differences in cerebral blood flow were 
observed between the two groups. In another 
study, epinephrine 45 pg/kg was compared to 
norepinephrine 45 &kg and placebo in 21 pigs in 
a blinded fashion [65]. Each pig underwent 5 min 
of cardiopulmonary arrest followed by 3 min of 
open-chest cardiac massage. After 3 min of CPR, 
the study drugs were administered. Both 
epinephrine and norepinephrine significantly im- 
proved cerebral blood flow compared to the con- 
trol group (P < 0.05). However, there was no 
significant difference between the epinephrine and 
norepinephrine groups (54 f 14 ml/min per 100 g 
vs. 58 i 22 ml/mm per 100 g post drug adminis- 
tration, respectively). Cerebral oxygen delivery 
also improved to a similar extent following 
epinephrine and norepinephrine administration 
(7.4 f 1.7 ml/mm per 100 g vs. 7.3 f 2.7 ml/min 
per 100 g, respectively). 
Overall, these studies suggest that epinephrine 
improves cerebral blood flow to a greater extent 
and more consistently than pure al-agonists such 
as phenylephrine and methoxamine. However, 
higher doses of the selective al-agonists may have 
effects similar to epinephrine. In contrast, it ap- 
pears that norepinephrine, which lacks &-agonist 
properties, improves cerebral measurements to a 
similar degree as epinephrine. Norepinephrine 
may therefore prove to be equally efficacious dur- 
ing CPR. 
3.4. Human experience 
There are a limited number of studies compar- 
ing different vasoactive agents during ventricular 
fibrillation in patients due to the difficulties of per- 
forming studies in this population. In one double- 
blind study, intravenous phenylephrine 1 .O mg was 
compared to intravenous epinephrine 0.5 mg in 65 
patients with out-of-hospital cardiac arrests (ven- 
tricular fibrillation, asystole, electromechanical 
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dissociation) [3]. Twenty-eight percent of patients 
were resuscitated with epinephrine compared to 
31% of those in the phenylephrine group. From 
these results there appears to be no difference be- 
tween epinephrine and phenylephrine in resuscita- 
tion rates. However, there are a number of 
limitations in this study which makes the conclu- 
sion questionable. One limitation is the dose of 
epinephrine used is probably too low to be effec- 
tive which does not allow for adequate trial of the 
drug [4]. Another limitation of the study is that the 
number of patients evaluated may be too small to 
detect any true differences between the two groups 
(Type II error). Finally, equivalent pressor doses 
of these agents were not evaluated which makes 
comparison of these agents in this study difficult. 
Perhaps a more comparable study design would be 
to administer a dose of epinephrine that has been 
shown to improve coronary perfusion pressure 
and survival in animals and compare this to an 
equivalent pressor dose of phenylephrine. 
The effects of intravenous epinephrine 0.5 mg 
and methoxamine 5 mg were evaluated in 102 pa- 
tients with ventricular fibrillation in a randomized 
double-blinded study [2]. The percentage of pa- 
tients who were successfully resuscitated (defined 
as having a pulse and rhythm upon arrival to the 
emergency department) was significantly greater 
with epinephrine treatment as compared to 
methoxamine (39.2% vs. 17.7%, respectively; P < 
0.02). In addition, the percentage of patients alive 
after hospitalization was also greater after 
epinephrine administration as compared to 
methoxamine (19.6% vs. 7.8%, respectively; P < 
0.07). These results suggest that epinephrine is su- 
perior to methoxamine for improving resuscitation 
and survival in the doses studied. 
A third study prospectively evaluated the effects 
of epinephrine 1 mg and norepinephrine 1 mg in 50 
patients with out-of-hospital ventricular fibrilla- 
tion in a randomized ,and blinded manner [66]. 
If the first dose of either epinephrine or 
norepinephrine failed to restore spontaneous 
circulation, standard guidelines for advanced car- 
diac life support were implemented. Resuscitation 
was defined as sustaining a systolic blood pressure 
> 80 mmHg for > 12 h. Initial successful resuscita- 
tion occurred in six of 25 patients following 
epinephrine and defibrillation and in 14 of 25 pa- 
tients following norepinephrine and defibrillation 
(P < 0.05). In addition, the number of patients 
resuscitated following additional advanced life 
support was significantly higher in the norepi- 
nephrine group compared to the epinephrine 
group (16 of 25 vs. 8 of 25, respectively). However, 
there was no difference in hospital discharge rate 
for norepinephrine (six of 25) or epinephrine (four 
of 25). Ventricular arrhythmias were observed in 
six of eight epinephrine and eight of 16 
norepinephrine patients 60 min after cardiopul- 
monary resuscitation. In addition to the small 
sample size, a limitation of this study is that it is 
unknown if the doses of norepinephrine and 
epinephrine are equipotent in humans during 
CPR. 
A final study evaluated the effect of high-dose 
epinephrine (15 mg), high-dose norepinephrine (11 
mg), or standard-dose epinephrine (1 mg) in the 
initial treatment of prehospital cardiac arrest 
(including ventricular fibrillation, EMD, and 
asystole) [67]. A total of 8 16 patients were enrolled 
in this randomized, prospective, double-blind 
clinical trial. The results demonstrated no differ- 
ence between epinephrine and norepinephrine for 
return of spontaneous circulation in the field, ad- 
mission to hospital, hospital discharge, and 
Cerebral Performance Category score. However, 
high-dose epinephrine did have a greater percen- 
tage of patients admitted to the hospital than 
norepinephrine (18% vs. 13%, respectively) 
whereas norepinephrine had the highest percen- 
tage of patients discharged from the hospital (2.6% 
vs. 1.7%, respectively). These findings need to be 
evaluated with caution since the major end point, 
hospital discharge, probably did not have suffi- 
cient power to detect a difference since the number 
of patients that survived was low (n = 18). In addi- 
tion, arrest to drug interval was long (16 min) 
which suggests that the ability for drug therapy to 
improve survival may have been compromised. In 
context of these limitations the results of this study 
suggest that there is no difference between 
epinephrine and norepinephrine in regards to the 
treatment of cardiac arrest. 
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4. Pulseless electrical activity (PEA) 
Pulseless electrical activity (PEA) is a situation 
in which there is no pulse in the presence of 
organized electrical activity that is expected to 
produce a pulse. PEA has a broad differential 
diagnosis, including treatable conditions (hypo- 
volemia, tension pneumothorax, tamponade, etc.) 
and true electromechanical dissociation (EMD). 
True EMD occurs when there is a regular electrical 
rhythm without mechanical contraction of heart 
muscle, no mechanical systole, and therefore no 
pulse. The likelihood of survival in patients with 
true EMD or PEA without a treatable condition is 
considered poor. In the treatment of PEA, 
epinephrine is currently considered first line thera- 
py. There are a limited number of studies compar- 
ing epinephrine to other adrenergic agonists 
during PEA. 
Epinephrine and methoxamine were compared 
in 80 patients with EMD in a prospective, rando- 
mized, double-blinded study [68]. Epinephrine 1 
mg or methoxamine 10 mg were administered in- 
travenously according to the ACLS algorithm [I]. 
Twenty-two patients receiving methoxamine and 
22 patients receiving epinephrine survived less 
than one hour, 15 patients receiving methoxamine 
and 13 patients receiving epinephrine survived l-6 
h, three patients receiving methoxamine and two 
patients receiving epinephrine survived more than 
24 h but not to discharge, and only one patient 
receiving epinephrine survived to discharge. From 
these results it appears that there is no difference 
between epinephrine and methoxamine for im- 
proving survival post EMD. The extremely poor 
survival illustrates the prognosis of true EMD and 
the importance of seeking and correcting the other 
causes of PEA. 
5. Conclusions 
Overall, from the data presented, it appears that 
phenylephrine and methoxamine offer no advan- 
tage in improving survival, coronary perfusion 
pressure, cerebral blood flow, or myocardial oxy- 
gen demand compared to epinephrine. There are 
data to suggest that epinephrine may even be supe- 
rior to these agents. However, species-dependent 
effects may be a consideration with these drugs. 
According to the limited data available from ani- 
mal and human studies, norepinephrine and 
epinephrine appear to have similar efficacy in the 
treatment of ventricular fibrillation. Further stud- 
ies are needed to determine if the absence of & 
adrenergic activity with norepinephrine is 
beneficial compared to epinephrine. Until further 
studies are performed (specifically, in humans), 
epinephrine remains the adrenergic agonist of 
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